Table 2.
Antibiotic susceptibility pattern of GNB and Staphylococcus aureus.
| Antibiotics | Enterobacteriaceae (n = 62) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Enterobacter spp. (n = 19) | Klebsiella spp. (n = 18) | Serratia spp. (n = 10) | Proteus spp. (n = 8) | Citrobacter spp. (n = 5) | E. coli (n = 2) | P. aeruginosa (n = 18) | Acinetobacter (n = 6) | S. aureus (n = 47) | |
| Penicillin | — | — | — | — | — | — | — | — | 25 (53.2%) |
| Ampicillin | 19 (100%) | 18 (100%) | 10 (10%) | 5 (63%) | 4 (80%) | 1 (50%) | — | — | — |
| Amoxicillin-clavulanic acid | 18 (95%) | 15 (83.3%) | 10 (100%) | 3 (38%) | 5 (100%) | 1 (50%) | — | — | — |
| Piperacillin | 7 (36.8%) | 10 (55.6%) | 10 (100%) | 00 | 3 (60%) | 1 (50%) | 8 (44.4%) | 5 (83%) | — |
| Piperacillin + tazobactam | 4 (21%) | 1 (5.6%) | 2 (20%) | 00 | 1 (20%) | 00 | 4 (22.2%) | 3 (50%) | — |
| Ticarcillin | 11 (57.9%) | 13 (72.2%) | 9 (90%) | 00 | 3 (60%) | 00 | 8 (44.4%) | 5 (83%) | — |
| Ceftriaxone | 11 (57.9%) | 5 (27.8%) | 2 (20%) | 4 (50%) | 1 (20%) | 00 | — | 4 (67%) | — |
| Ceftazidime | 8 (42.1%) | 6 (33.3%) | 2 (20%) | 0 (13%) | 1 (20%) | 1 (50%) | 8 (44.4%) | 4 (67%) | — |
| Cefepime | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | — |
| Cefoxitin | 8 (42.1%) | 6 (33.3%) | 8 (80%) | 00 | 1 (20%) | 2 (100%) | — | — | 21 (44.7%) |
| Erythromycin | — | — | — | — | — | — | — | — | 26 (55.3%) |
| Imipenem | 00 (00%) | 00 (0%) | 00 (0%) | 00 | 00 | 00 | 1 (5.6%) | 3 (50%) | — |
| Chloramphenicol | 6 (31.6%) | 10 (55.6%) | 00 (0%) | 5 (63%) | 2 (40%) | 00 | — | — | 21 (44.7%) |
| Gentamicin | 10 (52.6%) | 1 (5.6%) | 8 (80%) | 2 (25%) | 1 (20%) | 00 | 8 (44.4%) | 2 (33.3%) | 19 (40.4%) |
| Kanamycin | — | — | — | — | — | — | — | — | 27 (57.4%) |
| Tetracycline | 14 (73.7%) | 7 (38.9%) | 7 (70%) | 2 (25%) | 1 (20%) | 1 (50%) | — | 5 (83%) | 25 (53.2%) |
| Ciprofloxacin | 5 (26.3%) | 6 (33.3%) | 5 (50%) | 7 (88%) | 3 (60%) | 00 | 10 (55.6%) | 2 (33.3%) | 29 (61.7%) |
| Levofloxacin | 4 (21%) | 4 (22.2%) | 2 (20%) | 1 (13%) | 1 (20%) | 00 | 8 (44.4%) | 5 (83%) | 6 (12.8%) |
| Fusidic acid | — | — | — | — | — | — | — | — | 16 (34.04%) |
| Trimethoprim-sulfamethoxazol | 9 (47.37%) | 8 (44.4%) | 2 (20%) | 3 (38%) | 2 (40%) | 2 (100%) | — | — | 19 (40.4%) |
| ESBL | 8 (42.11%) | 9 (50%) | 2 (20%) | 00 | 00 | 1 (50%) | — | — | — |
—: not applicable; ESBL: extended-spectrum beta-lactamase.